FcγRIIB specific antibodies and methods of use thereof

• US 8,187,593 B2
• Filed: 07/03/2008
• Issued: 05/29/2012
• Est. Priority Date: 08/14/2002
• Status: Active Grant

• Current Assignee: MacroGenics, Inc.
• Original Assignee: MacroGenics, Inc.
• Inventors: Koenig, Scott, Veri, Maria Concetta, Tuaillon, Nadine, Bonvini, Ezio
• Primary Examiner(s): DAHLE, CHUN WU
• Application Number:
  US12/167,760
• Publication Number:
  US 20090053218A1
• Time in Patent Office: 1,426 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A01K 2267/0331 Animal model for proliferative diseases
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C07K 16/283 against Fc-receptors, e.g. CD16, CD32, CD64 CD23 C07K16/2851
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin'"'"'s lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition.

Claims

1. A method for treating or ameliorating a B-cell malignancy or one or more symptoms thereof in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of a Fcγ

RIIB-specific antibody or antigen binding fragment thereof;

wherein said Fcγ

RIIB-specific antibody comprises a variable domain, wherein said Fcγ

RIIB-specific antibody or fragment thereof is produced from clone 2B6, having ATCC Accession No. PTA-4591, or from clone 3H7, having ATCC Accession No. PTA-4592, and wherein said antibody and said fragment thereof bind Fcγ

RIIB via said variable domain and bind to said Fcγ

RIIB with greater affinity than said antibody or fragment thereof bind Fcγ

RIIA.

2. The method of claim 1, wherein administration of said therapeutically effective amount of said Fcγ

RIIB-specific antibody prolongs the survival of said subject.

3. The method of claim 1, wherein said subject is human.

4. The method of claim 1, wherein the antibody is a humanized or chimeric version of the 2B6 antibody that comprises the six CDRs of the antibody produced by said clone 2B6, or is a humanized or chimeric version of the 3H7 antibody that comprises the six CDRs of the antibody produced by said clone 3H7.

5. The method of claim 1, wherein the antibody competes for binding with the antibody produced by clone 2B6, having ATCC Accession No. PTA-4591.

6. The method of claim 1, wherein said B-cell malignancy is a B-cell lymphocytic leukemia or non-Hodgkin'"'"'s lymphoma.

7. The method of claim 1, wherein said Fcγ

RIIB-specific antibody is conjugated to a therapeutic agent or drug.

8. The method of claim 7, wherein the therapeutic agent is a heterologous polypeptide.

9. The method of claim 7, wherein the therapeutic agent is an antibody that immunospecifically binds to a cell surface receptor other than Fcγ

RIIB.

10. The method of claim 7, wherein the therapeutic agent is an antibody that immunospecifically binds to a tumor-associated antigen.

11. The method of claim 1 further comprising administering to said subject a therapeutically effective amount of one or more additional therapies for a B-cell malignancy.

12. The method of claim 11, wherein the additional therapy is selected from the group consisting of antibody therapy, cytokine therapy, chemotherapy, hematopoietic stem cell transplantation, radiation therapy, hormonal therapy, and surgery.

13. The method of claim 11, wherein said additional therapies are administered prior to, concomitantly with, or subsequent to the administration of said Fcγ

RIIB-specific antibody or an antigen-binding fragment thereof.

14. The method of claim 1, wherein said subject has previously been treated by the administration of one or more standard or experimental therapies for a B-cell malignancy but not by the administration of an antibody or an antigen-binding fragment thereof that immunospecifically binds Fcγ

RIIB.

15. The method of claim 1, wherein said Fcγ

RIIB-specific antibody is administered intravenously, subcutaneously, intramuscularly, orally, or intranasally.